Organization
Renmin Hospital of Wuhan University
4 clinical trials
6 abstracts
Abstract
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Second Department of Thoracic Tumors, Peking University Cancer Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology,
Abstract
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.Org: Fudan University Shanghai Cancer Center, The Second Hospital of Dalian Medical University, Harbin Medical University Cancer Hospital, Liaoning Cancer Hospital & Institute, Shenyang, China, Hunan Cancer Hospital,
Abstract
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Yunnan Cancer Hospital, Kunming, China, Sun Yat-sen University Cancer Center, Guang Zhou, China,
Clinical trial
Effectiveness and Safety of Early Administration of Heparin at First Medical Contact for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: a Multicenter, Prospective, Randomized, Controlled StudyStatus: Active (not recruiting), Estimated PCD: 2023-08-20
Clinical trial
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction(G/GEJ) Adenocarcinoma Patients With Poor Prognosis: A Prospective Exploratory StudyStatus: Completed, Estimated PCD: 2023-03-01
Clinical trial
Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein OcclusionStatus: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
Chemoradiation Versus Chemotherapy in Combination With Tislelizumab as First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma With Low PD-L1 Expression (RENMIN-236): Multicentre, Randomised, Phase 3 TrialStatus: Recruiting, Estimated PCD: 2026-07-01
Abstract
Construction of DNA methylation-based biomarkers for diagnosis of hepatocellular carcinoma.Org: Renmin Hospital of Wuhan University, Wuhan University,
Abstract
Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.Org: Renmin Hospital of Wuhan University, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, The Central Hospital of Xiao Gan, Xiang Yang Central Hospital,
Abstract
Revealing distinct immune landscape in EGFR mutant and EGFR wild type lung adenocarcinoma by using single-cell RNA sequencing.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Renmin Hospital of Wuhan University, Wuhan, China,